Abstract

Fenbendazole, a benzimidazole anthelmintic primarily used in veterinary medicine, has gained attention for its potential anticancer properties. This comprehensive review examines its mechanisms of action, preclinical and clinical research, safety considerations, and its possible role in integrative oncology in 2024.

1. Introduction

Repurposing drugs like Fenbendazole has become a promising avenue for novel anticancer therapies. This article delves into the latest research and insights regarding Fenbendazole and cancer in 2024.

2. Mechanisms of Action

• Microtubule Disruption: Fenbendazole inhibits microtubule formation, disrupting cancer cell division.
• Inhibition of Glucose Uptake: It interferes with cancer cells’ glucose metabolism, reducing their energy supply.
• Induction of Apoptosis: Fenbendazole promotes programmed cell death in cancer cells.

These mechanisms make Fenbendazole a multi-targeted agent with significant anticancer potential.

3. Preclinical Research

Research highlights Fenbendazole’s effectiveness against various cancer types:

• Colorectal Cancer: It demonstrated efficacy against 5-FU-resistant colorectal cells.
• Lymphoma: Studies showed anticancer effects in mouse lymphoma models.

These findings underscore the importance of further clinical trials to validate its effectiveness in humans.

4. Clinical Research and Case Reports

While no large-scale clinical trials have been conducted, anecdotal evidence suggests Fenbendazole’s potential benefits in cancer treatment. Protocols like the Joe Tippens regimen highlight its possible integration into alternative therapies.

5. Safety and Regulatory Considerations

Fenbendazole is currently approved for veterinary use only. Patients should consult healthcare professionals before considering its use.

6. Integrative Oncology and Future Directions

Integrative oncology protocols incorporating Fenbendazole are being explored. One such approach, the Hybrid Orthomolecular Protocol, combines Fenbendazole with other agents to target metabolic pathways and cancer stem cells.

7. Conclusion

Fenbendazole offers promising possibilities in cancer treatment by targeting microtubules, metabolic pathways, and apoptosis. However, rigorous clinical trials are essential to validate its safety and efficacy. As of 2024, its role in cancer therapy remains experimental and requires careful medical supervision.